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Abstract Personalized cancer care requires reliable bio-
markers. While the BRAF V600E mutation is implemented
in the clinic, no method for its detection has so far been
established as reference. We aimed to perform a comprehen-
sive comparison of three methods currently being used for
V600E detection in clinical samples. We analysed genomic
DNA from 127 malignant melanomas (77 patients) and 389
tumours from 141 colorectal cancer patients (383 liver metas-
tases and 6 primary tumours) by Sanger sequencing and a
single probe-based high-resolution melting assay (LightMix).
Formalin-fixed paraffin-embedded (FFPE) tissue from a sub-
set of these lesions (n=77 and 304, respectively) was analysed
by immunohistochemistry (IHC) using the V600E-specific
antibody VE1. In a dilution series of V600E-mutated DNA
in wild-type DNA, the detection limit for the LightMix assay
was 1:1000 mutated alleles while it was 1:10 for Sanger
sequencing. In line with this, we detected 15 additional mu-
tated melanoma samples and two additional mutated metasta-
tic colorectal cancer samples by the LightMix assay compared
to Sanger sequencing. For the melanoma samples, we ob-
served high concordance between DNA-based methods and
analysis by IHC. However, in colorectal samples, IHC per-
formed poorly with 12 samples being scored as V600E pos-
itive exclusively by IHC and nine samples being scored as
V600E negative exclusively by IHC. In conclusion, the VE1
antibody is not recommendable for clinical tests of colorectal
cancer samples. For melanoma samples, IHCmay be useful as
a screening tool guiding further analytical approaches.
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Introduction
In the era of personalized cancer care, reliable detection
methods for biomarkers are utterly important. A biomarker
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already implemented in the clinic is the BRAF V600E muta-
tion. In malignant melanoma (MM), this mutation (and to a
smaller extent the less frequent V600K mutation) indicates
utility of BRAF inhibitors (such as vemurafenib and
dabrafenib) [1, 2], whereas in colorectal cancer (CRC),
V600E is suspected to account for resistance to EGFR anti-
bodies in patients harbouring KRAS wild-type tumours [3, 4]
as well as indicating a dismal prognosis [5]. Currently, the
BRAF V600E is also evaluated in CRC in algorithms for
screening for Lynch syndrome [6, 7].
For several years, Sanger sequencing has been considered
the reference method for detection of specific mutations in
human tumours, including BRAF V600E and V600K [8],
although a “gold standard” detection method for these muta-
tions in diagnostic laboratories is yet to be established.
Undoubtedly, with the growing interest in biomarkers, mas-
sive parallel sequencing will soon become cost-effective and
will, in the coming years, be implemented in diagnostic pa-
thology laboratories. This technology will provide BRAF sta-
tus along with a large number of other biomarkers. However,
single biomarker assays will still remain important as
confirmative assays, and they will also be used for cito
diagnostics and in low-quality tissues. Regarding
targeted analysis of BRAF V600E, Capper et al. report-
ed in 2011 a novel mutation-specific antibody (VE1)
allowing detection of V600E-mutated cells by immuno-
histochemistry (IHC) in paraffin-embedded archive sam-
ples (FFPE) [9]. The sensitivity as well as specificity
for this antibody was reported to be 100 % for both
malignant melanoma species and in papillary thyroid
carcinoma. While some subsequent studies have con-
firmed the value of the VE1 antibody in several tumour
forms [10–16], notably, it has also been reported to be
of uncertain value in analyses of colorectal carcinomas,
due to insufficient sensitivity [17].
For detection of the BRAF V600E mutation at the DNA
level, several methods including Sanger sequencing, pyro-
sequencing, high-resolution melting assays (HRMAs),
dHPLC, TaqMan assays as well as massive parallel sequenc-
ing have been utilized [18–23]. Notably, in the BRIM-3 phase
3 trial, leading to vemurafenib being approved for clinical use
in patients with metastatic MM, a real-time PCR assay (cobas
4800 BRAF V600 Mutation Test, Roche Molecular Systems)
was used to define mutation status [1].
Some investigators have suggested that IHC might be used
as a first-line method to screen for the V600E mutation due to
its high specificity, while DNA-based methods should be
performed for samples scored as staining-negative or uninter-
pretable cases [8, 23]. This approach resembles to a large
extent the strategy established for HER2 testing in breast
cancer, where IHC is used for initial testing, while CISH/
FISH is applied for cases scored as 2+ by IHC staining
(Norwegian national guidelines; www.nbcg.no, April 2014).
Here, we present a comprehensive comparison of three
BRAF V600E detection methods including immunohisto-
chemistry (IHC) using the mutation-specific monoclonal an-
tibody (VE1), Sanger sequencing and a single probe-based
high-resolution melting assay (LightMix) with a clamped
wild-type allele amplification, leading to an expected higher
sensitivity. Importantly, we compare all three methods across
both melanoma and colorectal cancer specimens.
Material and methods
Patient specimens
The numbers of samples analysed with the three different
methods are listed in Fig. 1. Genomic DNA (gDNA) from
127 metastatic deposits obtained from 77 patients with meta-
static malignant melanoma was selected from a previously
described study including a total of 85 patients. BRAF V600
status assessed by Sanger sequencing has previously been
reported for these patients [24]. Here, we did not analyse
samples previously found to be NRAS mutated, as BRAF
and NRAS mutations are mutually exclusive [25, 26].
Formalin-fixed paraffin-embedded (FFPE) tissue from 77 me-
tastases from 44 of these patients was available for IHC
staining.
Genomic DNA was isolated from 389 tumours from 141
patients suffering from metastatic colorectal cancer (mCRC)
(383 surgically removed liver metastases and six primary
tumours). Further, FFPE tissue from 304 liver metastases from
125 of these patients was subjected to immunohistochemical
staining. Thus, for most patients, two or more individual
lesions were analysed.
Genomic DNA from all patient samples used was extracted
from fresh frozen tissue using the QIAamp DNA Mini Kit,
(QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions, and the two DNA-based methods were per-
formed on DNA from the same extracted aliquot for each
sample.
One part of each biopsy sampled was, if possible, formalin-
fixed and paraffin-embedded for assessment of tumour con-
tent. For direct comparison between methods, we used the 64
melanoma samples (from 38 patients) and the 99 colorectal
samples (from 39 patients) successfully analysed by all three
methods (Fig. 1).
The sample collection was approved by the regional ethical
committee, and all patients provided written informed consent
before tissue sampling.
DNA pre-amplification
Genomic DNA (gDNA) from the metastatic colorectal cancer
samples was globally amplified using the REPLI-g Midi Kit
1004 Tumor Biol. (2015) 36:1003–1013
(QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. In brief, gDNA was incubated in denaturation
buffer for 3 min before addition of neutralization buffer and a
master mix containing phi29 DNA polymerase with exonu-
clease proofreading activity. The isothermal amplification re-
action was carried out overnight at 30 °C. This procedure was
performed in order to save patient material in our research
laboratory; however it is not required to perform the analyses
evaluated.
Dilution series
In order to generate a dilution series for assessment of
sensitivity limits for the DNA-based methods, we used PCR
products carrying wild-type BRAF or BRAF V600E. These
PCR products were generated from a cell line (A2058) het-
erozygote for the V600E mutation. We added known amounts
of mutated DNA fragments to the wild-type products. The
ratio spanning from 1:1 to 1:107 mutated vs wild-type
molecules.
PCR amplification and Sanger sequencing
BRAF, exon 15 (harbouring codon 600), was amplified using
the DyNazyme EXT polymerase system (Finnzymes, Espoo,
Finland) according to the manufacturer’s instructions with
forward primer 5′-tca taa tgc ttg ctc tga tag ga-3′ and reverse
primer 5′-ggc caa aaa ttt aat cag tgg a-3′. Thermocycling
conditions were an initial step at 94 °C for 5 min, 35 cycles
at 94 °C for 30 s, 56 °C for 30 s and 72 °C for 30 s, followed
by a final step at 72 °C for 7 min. The resulting PCR products
were sequenced using Big Dye v1.1 terminator mixture
(Applied Biosystems, Carlsbad, CA). All sequencing reac-
tions were carried out with the same primers as used for
PCR amplification. For most samples, only the forward prim-
er was used, but all alterations other than V600E were verified
by a second sequencing reaction using the reverse primer.
After an initial step of 5 min denaturation at 94 °C, the
sequencing reaction was carried out for 30 cycles of 15 s at
94 °C, 5 s at 50 °C and 4 min at 60 °C. Capillary gel
electrophoresis, data collection and sequence analyses were
performed on an automated ABI 3700 DNA sequencer
(Applied Biosystems, Carlsbad, CA). PCR amplification and
Sanger sequencing of the CRC samples were performed on
pre-amplified gDNA. All alterations detected were verified in
an independent amplification using original gDNA as
template.
High-resolution melting assay
For high-resolution melting analysis of V600 status, we used a
single probe-based assay specifically designed to detect both
BRAF V600E and V600K (LightMix® Kit BRAF V600E/K,
2013 version, including a control reaction; TIB MOLBIOL,
Berlin, Germany) according to the manufacturer’s instruc-
tions. Two separate reactions were performed for each sample:
a mutation-specific reaction where amplification from BRAF
wild-type template was clamped and a control reaction
Fig. 1 Flow chart illustrating the number of samples and patients
analysed by the three different methods (a; melanoma, b; colorectal
cancer). The subset of samples analysed by the LightMix assay for the
CRC samples includes both positive and negative samples as character-
ized by Sanger sequencing as well as all discrepant cases within samples
from one patient and between methods (Sanger vs IHC). For direct
comparison between methods, we used the 64 melanoma samples and
the 99 colorectal samples successfully analysed by all three methods.
Notably, two of the melanoma samples were not interpretable by the
LightMix assay. Further, 13 of the melanoma samples and 19 of the CRC
samples were not interpretable by IHC (for details, see Supplementary
Table S1)
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included in order to verify DNA quality in samples negative
for the mutation-specific reaction. All reactions were per-
formed using the Roche Diagnostics LigthCycler FastStart
DNA Master Hybridization Probe reaction mix and run on a
LigthCycler 480 instrument (Roche, Basel, Switzerland). The
thermocycling conditions were as follows: denaturation at
95 °C for 10 min, amplification of target DNA; 25 cycles at
95 °C for 5 s, 58 °C for 10 s and 72 °C for 15 s; cycling and
quantification through 40 cycles at 95 °C for 5 s, 81 °C for
30 s, 58 °C for 5 s acquisition, 58 °C for 10 s and 72 °C for
15 s; melting at 95 °C for 20 s, 58 °C for 20 s, 43 °C for 20 s
and then a gradual increase in temperature to 75 °C with
continuous acquisition before cooling at 40 °C. Genotype
calling based on melting curves was performed using the
LightCycler 480 software release 1.5.1 (Roche).
Immunohistochemistry
Immunohistochemical staining was performed on 3–4 μm
sections of FFPE tissue (the mCRC samples were arranged
in tissue microarrays (TMAs), for the MM samples whole
section slides were used), placed on coated glass slides and
dried at 70 °C for 30 min. The staining procedure was per-
formed the same day or the day after the sectioning on a
Ventana BenchMark XT immunostainer (Ventana Medical
Systems, Tucson, AZ). The sections were de-paraffinized
using EZ Prep (Ventana Medical Systems) at 72 °C for
4 min. Heat pre-treatment for epitope retrieval was performed
using CC1 solution (Ventana) containing Tris/borate/EDTA
(pH 8.2) for 64 min at 99 °C. Slides were incubated with
BRAF V600E-specific monoclonal mouse antibody clone
VE1 (Spring Bioscience, Pleasanton, CA) diluted 1:60 in an
antibody diluent (50 mM Tris, 150 mM NaCl, 1 % BSA,
0.01 % Na-Acid, 0.05 % Tween 20; pH 7.5), at 36 °C for
16 min. Following incubation with primary antibody, slides
were treated with peroxidase inhibitor (3 % H2O2) for 4 min,
HQ universal linker for 8 min, HRP multimer for 8 min, DAB
for 8 min and copper (copper sulphate, 5 g/l) for 4 min, at
37 °C. Primary antibody detection was performed using the
OptiView universal DAB Detection Kit from Ventana.
Counterstaining was performed with Harris haematoxylin
(Histolab Products AB, Gothenburg, Sweden) for 30 s at room
temperature. Finally, the sections were blueing in running tap
water for 2 min, dehydrated in alcohol solutions and xylene
and mounted in Mountex (Histolab Products AB,
Gothenburg, Sweden). A detailed description of all steps in
the establishment of the IHC procedure is included as a
separate section in the online supplementary information.
BRAF-VE1 staining was seen exclusively in the cytoplasm.
The intensity of immune staining was graded 0 if no visible
staining, grade 1 if weak diffuse cytoplasmic background
staining, grade 2 if moderate diffuse and granular cytoplasmic
and grade 3 if strong mainly granular cytoplasmic staining
(Fig. 2). No staining and staining grade 1 were regarded as
negative for V600E. Grade 2 and grade 3 were regarded as
positive, as described by Bösmüller and Sinicrope [10, 14]. In
the positive samples, the staining was homogenous with equal
intensity throughout the majority of tumour cells. Each slide
was evaluated and scored independently by two of the authors
(I. M. L. and H. I.) blinded to the V600E screening results from
the twoDNA-basedmethods. Any inconsistencywas discussed
and agreed upon. In any case of discordance showing positive
results by IHC and negative mutation status by the DNA-based
methods in theMM samples, a new slide from the same tumour
was stained with haematoxylin only to detect and locate any
pigmentation of the tumour. If the haematoxylin-stained slide
revealed melanin (Fig. 2i) in all parts of the tumour, we would
change our conclusion to negative staining.
Evaluation of tumour content in biopsies
Before TMA production, all sections from the colorectal
samples were haematoxylin and eosin (HE) stained and eval-
uated for tumour content, including viable tumour cells, ne-
crosis and fibrosis as well as amount of normal tissue by an
experienced pathologist (H. I.). The amount of viable tumour
cells in the whole section slides was on average 81 % (range
10–100 %) with only five samples <30 %. The TMA cores
were made from areas found to contain viable tumour cells,
and then again evaluated by HE staining to ensure sufficient
tumour content in each core. Each TMA core was 1 mm in
diameter, and we used four cores from each sample to ensure
representative material (no differences between the four cores
from individual samples were recorded).
Results
Detection limits for DNA-based BRAF V600E analyses
In order to establish the detection limits for the DNA-based
methods used in the present comparison (Sanger sequencing
and the LightMix high-resolution melting assay) with respect
to detectable fraction V600E-mutated molecules among
BRAF wild-type molecules, we performed analyses on a dilu-
tion series containing BRAF V600E mutated in BRAF wild-
type DNA spanning a ratio from 1:1 to 1:107. We found the
detection limit for Sanger sequencing to be 1:10 while it was
1:1000 mutated alleles for the LightMix assay (Fig. 3).
BRAF analyses in melanoma specimens
Detailed results for each individual sample are listed in
Supplementary Table S1. Among 127 samples from 77 pa-
tients suffering from malignant melanoma, we found 60
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samples from 31 patients to be positive for BRAF mutations
(n=28, V600E; n=3, V600K) by Sanger sequencing.
Analysing the same samples by LightMix high-resolution
melting assay, we found 75 mutated samples from 37 patients
to harbour BRAFV600mutations. Thus, 15 samples classified
as harbouring wild-type BRAF by Sanger sequencing were
found to harbour V600 mutations (n=14, V600E; n=1,
V600K) by the LightMix assay. In all of the 60 samples found
mutation positive by Sanger sequencing, the same mutation
was confirmed by the LightMix assay, including the V600K
mutation.
Using the V600E-specific antibody VE1, we performed
immunohistochemical analysis on 77 samples from 44 pa-
tients. We found 39 samples from 24 patients to be positive
for V600E immunostaining. In total, 64 melanoma samples
from 38 patients were successfully analysed by all three
methods. A summary of the results for these 64 samples is
listed in Table 1. Out of the 64 samples, 44 samples yielded
positive results by at least one of the analytical methods
(Fig. 4a). Seven samples yielded discordant results: Five
samples for which the V600E mutation had been detected
by the LightMix assay were scored as negative by IHC; out
of these, three samples had been recorded as positive for
V600E by Sanger sequencing. Further, two samples were
scored as positive by the LightMix assay and IHC but nega-
tive by Sanger sequencing.
Four of the samples tested by IHC had been found to
harbour the V600K mutation by the DNA-based assays. As
expected, none of the tumours harbouring the V600K muta-
tion stained positive, and these samples thus represent true
negative controls.
BRAF analyses in colorectal cancer specimens
Although BRAF V600E is most applicable as a biomarker in
malignant melanoma, we aimed to extend our methods-
Fig. 2 Representative examples
of immunostaining distribution
and intensity observed in
metastatic colorectal cancer
samples (a–d) and malignant
melanoma samples (e–h).
Grading from negative to grade
3+ for V600E (left to right).
V600K mutated heavily
pigmented MM sample (i). TMA
section demonstrating the
uniform staining throughout all
tumour tissue (j). Original
magnification: 400× (a–i),
100× in (j)
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comparison to colorectal cancer, where BRAF status may also
have important implications.
Among 389 samples from 141 patients suffering from
metastatic colorectal cancer (mCRC), we found 22 samples
from seven different patients to be BRAF V600E mutated by
Sanger sequencing. In a selected subset of these samples (n=
127), the LightMix assay identified the same mutations. In
addition, two samples yielding negative results by Sanger
sequencing were found to harbour the V600E mutation by
the LightMix assay. The subset of samples analysed by the
LightMix assay included both positive and negative samples
as characterized by Sanger sequencing as well as all discrepant
cases within samples from one patient and between methods
(Sanger vs IHC).
Immunohistochemistry using the mutation-specific mono-
clonal antibody VE1 was performed on TMAs including
tissue from 304 metastases from 125 of the mCRC patients.
Twenty-five samples from 15 patients were found to be pos-
itive for V600E immunostaining. In total, 99 colorectal sam-
ples from 39 patients were successfully analysed by all three
methods. A summary of the results for these 99 samples is
listed in Table 2 (detailed results for each individual sample
are listed in Supplementary Table S1). Out of the 99 samples,
34 samples yielded positive results by at least one of the
analytical methods (Fig. 4b). Two samples revealed non-
V600E and non-V600K mutations, and 22 samples yielded
discordant results: Nine samples for which the V600E muta-
tion had been detected by the LightMix assay were scored as
Fig. 3 Electropherograms and
melting profiles (from Sanger
sequencing (left) and the
LightMix assay (right)) for a
dilution series containing a ratio
of 1:1–1:107 BRAF V600E-
mutated DNA in BRAF wild-type
DNA. (Only the four dilutions up
to 1:103 shown as all higher
dilutions gave results resembling
wild-type samples)
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negative by IHC; out of these, all nine had been recorded as
positive for V600E by Sanger sequencing. Further, one sam-
ple was scored as positive by the LightMix assay and IHC but
negative by Sanger sequencing, and 12 samples were scored
as positive by IHC but negative by both DNA-based methods.
Non-V600E/V600K mutations
Two non-V600E/V600K mutations were detected by Sanger
sequencing: a substitution at BRAF-coding nucleotide 1780
(c.1780G>A; COSMIC ID: COSM27639) and a three-
nucleot ide inser t ion at coding nucleot ide 1797
(c.1796_1797insTAC; COSMIC ID: COSM30730), previously
found to cause hyperactivity ofBRAF similar toV600E [27]. The
G1780Amutationwas not detected by the LightMix assay as it is
designed to detect V600E and V600Kmutations only. However,
Table 1 BRAF V600E mutation screening results in malignant melano-
ma samples
Screening results Number of samples
wt by all methods 16
V600E by all methods 37
V600K by DNA methods 4
Other exon 15 mutations 0
Discordanta 7
Total 64
aDistribution of results in discordant samples
Sample ID Sanger LightMix IHC Percentage of tumour cells
MM10-1 wt V600E V600E 50
MM25-3 V600E V600E wt 60
MM61-2 wt V600E V600E 20
MM61-3 V600E V600E wt 80
MM61-4 V600E V600E wt 70
MM71-2 wt V600E wt <10
MM78-1 wt V600E wt 30
Fig. 4 Venn diagrams illustrating the degree of concordance between the
threeBRAFV600E detectionmethods evaluated for malignant melanoma
samples (a) and colorectal cancer samples (b). Only samples analysed by
all three methods and yielding positive results in at least one analysis are
included (melanoma: n=44, colorectal cancer: n=34)
Table 2 BRAF V600E mutation screening results in colorectal cancer
samples
Screening results Number of samples
wt by all methods 63
V600E by all methods 12
V600K by DNA methods 0
Other exon 15 mutations 2
Discordanta 22
Total 99
aDistribution of results in discordant samples
Sample ID Sanger LightMix IHC Percentage of tumour cells
t9-1 wt wt V600E 100
t9-3 wt wt V600E 100
t14-1 wt wt V600E 100
t15-1 wt V600E V600E 80
t26-5 wt wt V600E 80
t29-4 wt wt V600E 100
t30-2 wt wt V600E 20
t39-1 V600E V600E wt 100
t39-2 V600E V600E wt 90
t39-3 V600E V600E wt 90
t49-2 wt wt V600E 40
t58-8 wt wt V600E 50
t64-3 wt wt V600E 80
t64-4 wt wt V600E 80
t67-2 wt wt V600E 20
t75-1 V600E V600E wt 100
t75-3 V600E V600E wt 100
t84B-1 V600E V600E wt 100
t99-2 V600E V600E wt 100
t99-3 V600E V600E wt 90
t99-4 V600E V600E wt 60
t156-1 wt wt V600E 100
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due to its close location to the V600, the c.1796_1797insTAC
mutation was indicated in the melting point analyses as a shift in
melting temperature (Fig. 5). Notably, none of these two muta-
tions were detected by IHC using the VE1 antibody.
Costs, time consumption and tissue requirements
Costs, time consumption and amount of material used for the
three methods are listed in Table 3. Regarding costs, the two
DNA-based methods would be comparable at approximately
5 USD/sample. IHC would cost approximately 20 USD per
slide stained. However, using TMAs (in a research setting)
would allow for low costs for IHC as multiple samples may be
fitted on a single slide.
The LightMix analysis is completed in less than 4 h while
PCR and Sanger sequencing require at least 1 day. In both cases,
DNA must be isolated up front. IHC will not require DNA
isolation and thus is more readily available in a diagnostic labo-
ratory, but evaluation of stained sections bymicroscopy is needed.
The input of gDNA used to run the DNA-based methods
on patient samples was typically in the range of 50–100 ng for
the Sanger sequencing and 100–250 ng for the LightMix
assay respectively.
Discussion
Personalized medicine introduces several new questions of
importance to clinicians as well as researchers. As new bio-
markers are identified and implemented in the clinic to guide
treatment decisions, it is essential that reliable methods to
detect these alterations are available. Regarding the BRAF
V600E mutation, it has already been implemented as a pre-
dictive factor guiding therapy in malignant melanoma and is
currently explored as a potential predictive marker in colorec-
tal cancer as well as in other malignancies.
The V600Emutation occurs within the activating segment of
the kinase domain and leads to constitutive activation of the
mitogen-activated protein kinase (MAPK) pathway promoting
cell proliferation and preventing apoptosis [28]. Later publica-
tions have pointed out the importance of recognizing other
activating mutations in the same region [29]. The second most
commonBRAFV600mutation (V600K)which has demonstrat-
ed increased kinase activity as well [30] is currently accepted as
a predictive marker with respect to anti-BRAF therapy.
As massive parallel sequencing is continuously becoming
cheaper and more efficient, this technology will undoubtedly
be implemented in diagnostic laboratories for mutation detection
in tumour samples as well as in inherited diseases. However,
single biomarker assays will still remain important as
confirmative assays, and they will also be used for cito diagnos-
tics and in low-quality tissues. Comparing two DNA-based
mutation detection methods with immunohistochemistry, our
data show differences between these three methods with respect
to the detection of different BRAFmutations. Sanger sequencing
is specific and of course able to distinguish between V600E and
V600K mutations. This well-established DNA-based method
also enabled us to detect other alterations still of unknown
importance. Compared to the LightMix assay, however,
Sanger sequencing showed an inferior detection limit, indicating
that higher tumour cell content in the sample is required to detect
any genetic alterations. In the mCRC samples, we identified two
additional V600-mutated tumours by applying the melting point
assay. In the melanoma samples, we detected 15 additional
mutations. Eight of these tumours were from patient with other
mutation-positive tumours, but importantly, seven of these tu-
mours were from six different patients with tumours classified
by Sanger sequencing as wild type, and, thus, they would
potentially have been excluded from treatment with BRAF
inhibitors when relying on Sanger sequencing alone. A likely
explanation for this could be that only a small fraction of the
tumour cells in a sample harboured the mutation. Hence, a more
sensitive assay with clamped wild-type amplification, such as
the LightMix-assay, detects more mutations. For the moment,
BRAF inhibitors are limited to treatment of metastatic melano-
mas only. For such patients, the clinical benefit of diagnosing a
BRAFmutation in a very small fraction of the tumour cells may
be questioned. However, assuming clonal expansion of BRAF-
mutated cells due to their high growth rate, a negative result by
Sanger sequencing may preclude effective treatment at a later
stage, provided repeated sampling and testing are not performed.
Considering the potential for anti-BRAF therapy in the adjuvant
setting, a highly sensitive assay detecting minor subclones of
BRAF-mutated cells, able to set out metastases, could be highly
important. Another possible explanation is that all tumour cells
in a mutated sample harbour the mutation, but that the percent-
age of tumour cells in the sample is too low for Sanger
Fig. 5 Melting curve profiles illustrating the detection of a non-V600E/
V600K BRAF mutation (c.1796_1797insTAC) by a shifted melting tem-
perature in the LightMix assay
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sequencing to detect the mutation. This is supported by the fact
that for the IHC positive samples, the staining was homogenous
with equal intensity throughout the majority of tumour cells.
Mutation-specific immunohistochemistry for detection of
mutated BRAF protein introduced by Capper et al. in 2011
presented a method without the need for DNA isolation.
Several publications [9, 13–16] have pointed out VE1
antibody’s excellent sensitivity and specificity, and some in-
vestigators [8, 23] conclude that IHC might be used as a
screening for the mutation due to a 100 % specificity and that
the uncertain or negative samples are left to be analysed by
DNA-based methods. In line with these previous findings, we
observed high concordance between DNA-based methods
and IHC analysis in our melanoma samples. For all discrep-
ancies, IHC was negative while DNA analysis detected the
mutation. Thus, for melanoma, we find that IHC screening of
samples might be considered but that samples testing negative
for V600E should be subjects to DNA-based methods.
Importantly, we also assessed the performance of IHC in
colorectal cancer specimens. In our mCRC dataset, we see a
large discrepancy between the DNA-based methods and the
IHC data. Based on the IHC data, we would miss two mCRC
patients with the mutation, as well as suspect the mutation in
one or more tumours from ten patients found to be wild type
by the DNA-based assays. We do not have a full explanation
to this finding which presents as unspecific staining in the
colorectal cancer metastasis. One may speculate that this
staining could be due to cross reactions in samples with
particularly high levels of wild-type BRAF protein or toward
other proteins; at this stage, however, no conclusion can be
drawn. Nevertheless, unspecific staining does seem to occur, a
worrisome situation with respect to the use of the IHCmethod.
Especially since several diagnostic pathology laboratories
tend to choose IHC as a fast pre-screening tool. IHC also
had more uninterpretable cases, as compared to the DNA-
based methods which had very low failure rates. Notably, our
findings are in line with the results reported by Adackapara
et al. in 2013 [17], strongly indicating that although the VE1
antibody may be useful for melanoma samples, its value for
analysing colorectal cancer specimens is limited.
One could argue that our cutoffs for IHC are inaccurate, but
if only samples scored as 3+ with respect to staining were to
be considered positive, we would miss yet another mutated
sample and we would still have two patients suspected to have
mutated tumours despite negative DNA analysis. On the other
hand, if we were to include the 1+ samples as positive, like
Capper et al. did in their first paper [9], we would increase the
number of suspected mutations to 101/285 which would
clearly be wrong based on the data from the DNA-based
methods as well as the previously reported frequencies of
BRAF mutations in primary CRC (10 %) as well as in surgi-
cally removed metastasis (∼2 %) [31, 32]. Based on the DNA-
based methods, we detected a mutation frequency of 5 % in
our material which is slightly higher than that expected in
surgically removed liver metastases. BRAF-mutated colorectal
cancers have an unfavourable prognosis, and, thus, these
patients are less likely to experience liver-limited disease
and the option of surgical treatment of their metastases.
For melanoma samples, we found a relatively low mu-
tation frequency based on Sanger sequencing (40 %),
but using the more sensitive LightMix assay, we
reached a frequency of 48 %, closer to what is reported
in the literature (approximately 60 %) [28].
All samples were evaluated for tumour content by an
experienced pathologist, and it varied from 10 to 100 % (for
the CRC samples, only five harboured <30% tumour cells, for
the MM samples, 7). For the discrepant results, low tumour
cell content might explain the cases where the sample is
classified as wild type by Sanger sequencing only and as
mutated by IHC and LightMix. However, it cannot explain
the cases where IHC is negative while both the DNA-based
methods detect the mutation, and even more importantly, it
cannot explain the false positive results in the colorectal
cancer samples.
Conclusions
Taken together, our data indicate that for high sensitivity,
specific detection of BRAF V600E or V600K mutation, the
Table 3 Cost, time consumption and material input comparison of BRAF V600E detection methods
Cost per sample (USD) Time consumption (hands on) Material used
Sanger sequencingab 8 9 h (1 h) 50–100 ng
LightMix assayac 4, 5 4 h (1 h) 100–250 ng
Immunohistochemistryd 20 4 h (15 min) 3–4 μm section
a Time and costs for DNA isolation not included
b Capillary gel electrophoresis, data collection and sequence analyses were performed on an automated DNA sequencer (ABI 3700)
c All reactions were run on LigthCycler 480 instrument (Roche), and genotype calling based onmelting curves was performed using the LightCycler 480
software release 1.5.1 (Roche)
d The staining procedure was performed on a Ventana BenchMark XT immunostainer (Ventana Medical Systems)
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LightMix high-resolution melting assay would be preferable.
In order to be able to detect other mutations than these two
specifically, Sanger sequencing would still be the method of
choice despite its inferior sensitivity. IHC may be useful as a
screening tool guiding further analytical approaches for ma-
lignant melanomas, but for colorectal cancer samples, IHC
with the current antibody would not be recommendable for
clinical tests.
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